ATHENS, Ga. and SAN JOSE, Calif., Oct. 21, 2024–(BUSINESS WIRE)–Blue Lake Biotechnology, Inc. is a clinical-stage intranasal vaccine company developing a parainfluenza virus 5 (PIV5) vector vaccine. I am. Comprehensive Immune System Protection Against Serious Infections and its affiliate company CyanVac LLC today announced affirmations regarding BLB201, Blue Lake’s vaccine candidate for respiratory syncytial virus (RSV), at the 2024 ISV Annual Meeting. announced that they have released preliminary pediatric clinical data. in Seoul, South Korea. The oral presentation also included a discussion of Phase 1 clinical data for CVXGA, the company’s clinical-stage vaccine candidate for COVID-19.
Dr. Hong Jin, Chief Scientific Officer of Blue Lake and CyanVac, gave a lecture titled “PIV5 Vectored RSV and COVID-19 Intranasal Vaccine Shows Great Promise in Clinical Studies” and provided an interim analysis of RSV seropositivity. The results were also included. Children participating in the company’s ongoing Phase 1/2a pediatric study. Data demonstrated the safety and immunogenicity of BLB201 in this population, including RSV F-specific systemic and mucosal antibody responses and cellular immune responses in CD4+ and CD8+ T cells. Similarly, CVXGA’s Phase 1 clinical trial detected COVID S-specific systemic and mucosal antibody responses and T cell-mediated responses.
“Our vaccine approach is designed to stimulate a strong immune response from the humoral, cellular and mucosal pillars of the immune system,” said Biao He, CEO of Blue Lake and CyanVac. the doctor said. “Many currently available vaccine technologies, such as mRNA vaccines and protein-based vaccines, are administered intramuscularly and are therefore not effective at inducing mucosal immunity. They strongly stimulate all three pillars of immunity. By doing so, our intranasal vaccine may prevent disease transmission and generate longer-lasting immunity than other types of vaccines. ”
In addition to the clinical data that Dr. Jin presented at the conference, CyanVac scientist Dr. Christina Gingerich presented previous research on PIV5-based Lyme disease vaccines in a poster titled “Intranasal Parainfluenza Virus 5 (PIV5).” We plan to present clinical data. Lyme disease vaccine based on inducing protection against multistrain Borrelia burgdorferi tick challenge in mice. ”
The Lyme Disease Project is a collaboration between CyanVac and Immuno Technologies, Inc. and was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R44AI167605.
story continues
About CyanVac and Blue Lake Biotechnology
CyanVac LLC and its affiliate Blue Lake Biotechnology, Inc. optimize the immune system to keep people healthy, prevent serious infections, and protect the health of vulnerable populations. We are developing an intranasal vaccine to Our platform uses a proprietary parainfluenza virus 5 vector inserted with foreign genes from the targeted pathogen. We have generated a robust clinical-stage pipeline of best-in-class vaccines designed to overcome the limitations of existing vaccine technologies. Our lead product candidates have demonstrated potential for high efficacy and durability with few vaccine-related side effects.
For more information, please visit Blue Lake Biotechnology and CyanVac.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241020038518/en/
contact address
media contact
carolyn holey
Inizio Evoque Communication
carolyn.hawley@inizioevoke.com
619-849-5382
Company contact information
Samuel Wu, Chief Business Officer
Blue Lake Biotechnology, Inc. and CyanVac LLC
swu@chanvacllc.com
650-609-2231
